title: An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: we are willing to take a risk of serious adverse events for a doubtful benefit?
authors: Emanuele
authors: E
authors: Sinagra
authors: Claudia
authors: C
authors: Romano
authors: Roberto
authors: R
authors: Virdone
authors: Emanuele
authors: E
authors: Orlando
authors: Mario
authors: M
authors: Cottone
authors: Ambrogio
authors: A
authors: Orlando
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab; D016399:Lymphoma, T-Cell / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects*; D008875:Middle Aged
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D015122:Mercaptopurine